Waranya Rattanavipapong

Economic evaluation of<scp>HLA</scp>‐B*15:02 screening for carbamazepine‐induced severe adverse drug reactions in<scp>T</scp>hailand

Waranya Rattanavipapong, Tanunya Koopitakkajorn, Naiyana Praditsitthikorn et al. · Epilepsia · 2013 · 81 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacology +13

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?

Wantanee Kulpeng, Pattara Leelahavarong, Waranya Rattanavipapong et al. · Vaccine · 2013 · 55 citations

Veterinary Medicine, Infectious Diseases, Pharmacoeconomics +16

Landscape analysis of health technology assessment (HTA): systems and practices in Asia

Yot Teerawattananon, Waranya Rattanavipapong, Lydia Lin et al. · International Journal of Technology Assessment in Health Care · 2019 · 52 citations · Full text

Public Affairs, Health Policy, Health Systems +15

Prevention of non-communicable disease: best buys, wasted buys, and contestable buys

Wanrudee Isaranuwatchai, Yot Teerawattananon, Rachel A. Archer et al. · BMJ · 2020 · 44 citations · Full text

Medicine, Preventive Medicine, Public Health Practice +14

Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections

Wantanee Kulpeng, Vorasith Sornsrivichai, Virasakdi Chongsuvivatwong et al. · BMC Pediatrics · 2013 · 42 citations · Full text

Pharmacy, Child Health, Pediatrics +17